Hervolution ApS
HERVolution Therapeutics is engineering novel immunotherapies that target HERVs, a class of dark genome antigens impacting cancer, metabolic, and aging-related diseases. The company focuses on unlocking the therapeutic potential of HERVs to develop off-the-shelf immune therapies, with a pipeline of assets aimed at diseases of aging, cancer, and metabolic disorders. Their proprietary platform enables the design of highly immunogenic HERV antigens to stimulate potent immune responses, offering new hope for complex age-related diseases.
Industries
Nr. of Employees
small (1-50)
Hervolution ApS
Fuglebakken, Nordre Fasanvej 215 2000 Frederiksberg, Denmark
Products
HERV-K dual adenoviral vector immunotherapy (lead candidate)
A dual adenoviral vector immunotherapy designed to deliver a redesigned HERV-K antigen to induce concurrent antigen-specific T and B cell responses with low sensitivity to pre-existing anti-vector immunity; supported by preclinical data and advanced toward IND enabling and Phase 1 initiation.
HERV-K mRNA vector immunotherapy (booster candidate)
An mRNA-encoded redesigned HERV-K antigen intended for repeat dosing and for use as a booster to maintain or amplify adenoviral-initiated immune responses in a prime-boost regimen.
HERV-K dual adenoviral vector immunotherapy (lead candidate)
A dual adenoviral vector immunotherapy designed to deliver a redesigned HERV-K antigen to induce concurrent antigen-specific T and B cell responses with low sensitivity to pre-existing anti-vector immunity; supported by preclinical data and advanced toward IND enabling and Phase 1 initiation.
HERV-K mRNA vector immunotherapy (booster candidate)
An mRNA-encoded redesigned HERV-K antigen intended for repeat dosing and for use as a booster to maintain or amplify adenoviral-initiated immune responses in a prime-boost regimen.
Services
Collaborative clinical-grade manufacturing of vector- and particle-based immunotherapy assets to produce IND-enabling and clinical trial material.
Design and execution of in vitro and in vivo preclinical studies to evaluate immunogenicity and disease-model efficacy of redesigned antigens delivered by multiple vector platforms.
Clinical program design, regulatory planning, and trial execution oversight for early clinical evaluation of immunotherapy assets.
Collaborative clinical-grade manufacturing of vector- and particle-based immunotherapy assets to produce IND-enabling and clinical trial material.
Design and execution of in vitro and in vivo preclinical studies to evaluate immunogenicity and disease-model efficacy of redesigned antigens delivered by multiple vector platforms.
Clinical program design, regulatory planning, and trial execution oversight for early clinical evaluation of immunotherapy assets.
Expertise Areas
- HERV-targeted immunotherapy development
- Viral vector vaccine development
- mRNA vaccine development and prime-boost strategies
- Immunology and virology
Key Technologies
- Adenoviral vectors
- Virus-like particle vectors
- mRNA vector vaccines
- Antigen engineering
News & Updates
HERVolution announced the appointment of Dr. Tine Gaziel as Chief Medical Officer to oversee regulatory and clinical development of its HERV-targeting pipeline, including plans to initiate clinical evaluation in 2025.
HERVolution announced an $11.7 million Series A financing led by Serum Institute of India to support validation, manufacturing, and clinical trials of its HERV-targeted immunotherapies.
J. Robert Coleman was appointed as CEO to drive the development of immunotherapies targeting the dark genome for cancer, aging, and neurodegenerative diseases.
Research demonstrating the potential of an endogenous retrovirus vaccine combined with anti-PD1 therapy to eradicate tumors in mice.
A review discussing the expression of HERV proteins in cancer and potential therapeutic strategies.
Exploration of adenoviral vectors with modified antigen presentation for vaccine development.
HERVolution announced the appointment of Dr. Tine Gaziel as Chief Medical Officer to oversee regulatory and clinical development of its HERV-targeting pipeline, including plans to initiate clinical evaluation in 2025.
HERVolution announced an $11.7 million Series A financing led by Serum Institute of India to support validation, manufacturing, and clinical trials of its HERV-targeted immunotherapies.
J. Robert Coleman was appointed as CEO to drive the development of immunotherapies targeting the dark genome for cancer, aging, and neurodegenerative diseases.
Research demonstrating the potential of an endogenous retrovirus vaccine combined with anti-PD1 therapy to eradicate tumors in mice.
A review discussing the expression of HERV proteins in cancer and potential therapeutic strategies.
Exploration of adenoviral vectors with modified antigen presentation for vaccine development.